PDC and cancer: Although some PHD inhibitors are currently in clinical trials, potential side effects of targeting HIF via PHD inhibition should be taken into consideration, because both aberrant HIF activation and PHD knockdown are linked to the development of other diseases such as cancer and erythrocytosis [24,25].